WEKO3
アイテム
Preclinical evaluation of 11C-JNJ55511118 and 11C-JNJ56022486 for imaging subtype-selective AMPA receptor
https://repo.qst.go.jp/records/72838
https://repo.qst.go.jp/records/7283863ddb774-e07b-4a56-8676-c6458bad792c
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-06-29 | |||||
| タイトル | ||||||
| タイトル | Preclinical evaluation of 11C-JNJ55511118 and 11C-JNJ56022486 for imaging subtype-selective AMPA receptor | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Chen, Zhen
× Chen, Zhen× Zhang, Xiaofei× SHAO, TUO× Vasdev, Neil× Shao, Yihan× Tomita, Susumu× Zhang, Ming-Rong× Liang, Huan× 張 明栄× 梁 歓 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Objectives: Modulating transmembrane AMPA (a-Amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid) receptor regulatory proteins (TARPs) has emerged as a novel and alternative strategy towards pharmacotherapies for neuronal hyperactivity related CNS disorders such as epilepsy, PD, multiple sclerosis and schizophrenia. The development of TARP γ-8 subtype selective AMPA receptor antagonists, such as JNJ55511118 (1), JNJ56022486 (2) and LY3130481, is particularly promising for therapy and diagnosis of pathologic disorders within forebrain.[1][2] The goal of the project was to carry out 11C-isotopologue labeling of two novel TARP γ-8 dependent AMPA receptor antagonists JNJ55511118 and JNJ56022486, and perform preliminary PET studies and in vitro autoradiography in rodents. Methods: The synthesis of labeling precursor 5 was achieved through PdCl2(dtbpf)-catalyzed cross-coupling of aryl boric acid 3 with 4-bromobenzene-1,2-diamine 4. The precursor 8 was assembled via a sequence of PdCl2(dppf)-catalyzed coupling of aryl iodide 6 with 4-amino-3-nitrophenyl borate 7, followed by reduction Fe-mediated reduction in aqueous HCl solution. Subsequent treatment of diamine 5 and 8 with 1,1’-carbonyldiimidazole readily generated the corresponding standard 1 and 2, respectively. Radiosynthesis of [11C]1 and [11C]2 was performed using two 11C-carbonylation labeling strategies from [11C]COCl2 and [11C]CO2, respectively. Dynamic PET scans (60 min) were conducted in Sprague-Dawley rats. In vitro autoradiography (baseline and blocking) were also performed on frozen rat brain tissue to validate the binding specificity. Results: The standard compounds 1 and 2 were achieved in 50% yield over two steps and 61% yield over three steps, respectively, and their corresponding precursor 5 and 8 were obtained in 73% and 68% yields, respectively. Both 11C-carbonylayion strategies readily delivered the isotopologue of [11C]1 and [11C]2 in more than 10% isolated radiochemical yields (ca. 2.22 GBq; non-decay corrected from starting [11C]CO2) with high radiochemical purity (>99%) and high specific activity (greater than 40 GBq/μmol) within 45 min (end of synthesis). The compound [11C]1 synthesized either from [11C]COCl2 or [11C]CO2 showed no signs of radiolysis up to 90 min after formulation (10% ethanol in saline). In preliminary PET studies, while AMPA antagonist [11C]2 showed limited brain uptake (0.3 SUV), [11C]1 is brain permeable with peak uptake of 1 SUV. We further utilize in vitro autoradiography to confirm binding specificity of [11C]2, which showed heterogeneous distribution and reasonable bound radioactivity in the region of hippocampus, in accordance with the brain distribution of TARP γ-8 AMPA receptor. Pretreatment studies with JNJ56022486 (3 mg/kg) showed moderate binding with statistic significance compared to baseline study. Conclusions: We have successfully radiolabeled two potent TARP γ-8 dependent AMPA receptor antagonists in high radiochemical yields. In vivo PET study demonstrated the brain-penetration of [11C]1 and in vitro autoradiography confirmed the specific binding of [11C]2. Further characterization including blocking studies with structurally-diverse AMPA antagonists, ex vivo whole body distribution and radiometabolite analysis will be performed in order to evaluate and develop potent TARP γ-8 dependent AMPA receptor PET tracers. References: [1] J Pharmacol Exp Ther. 2016, 357, 394-414; [2] Nat Med. 2016, 22, 1496-1501. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | SNMMI 2018 Annual Meeting | |||||
| 発表年月日 | ||||||
| 日付 | 2018-06-24 | |||||
| 日付タイプ | Issued | |||||
